Exchange: NASDAQ·Updated 07:30 PM EST
PHAR logo

PHAR Pharming Group

$11.33
$0.63
(5.18%)
Today
Closed $11.54
$0.21
(1.82%)
After Hours
Reported EarningsOct 27
Mkt Cap$816.78M
Vol10,505.00

About PHAR

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
44

Bearish Sentiment

How do you feel about PHAR?

De_Monitor
$PHAR INVESTORS should watch $PHVS and $NTLA closely. Pharvaris is advancing a highly effective oral treatment for HAE attacks, while Intellia’s revolutionary one-time CRISPR therapy has shown sustained results for up to FOUR YEARS. Both face major regulatory milestones and could seriously disrupt the market Ruconest depends on. Two different technologies, one enormous threat to Pharming’s core business. Here’s the problem: Ruconest still generates approximately 80% of Pharming’s quarterly revenue. It’s the company’s only major revenue pillar, with Joenja still too small to offset a substantial decline. Pharvaris could replace injections with convenient pills, while Intellia could dramatically reduce the need for lifelong HAE medication. Regulatory approval and commercial success aren’t guaranteed, but the threat is increasingly real. The question is no longer whether Ruconest faces serious competition, but how much of its market will survive. $PHVS $NTLA
3
JFais
Days where low-volume, little-discussed names like $PHAR doing the heavy lifting for the portfolio 👍
1
Ruconestor
$PHAR Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025 Generated US$32.4 million in cash flow from operations in the quarter and US$24.7 million year to date, increasing cash position to US$190.9 million
1
De_Monitor
$PHAR Hey , only six trading days left in November after today. Remember your promise to share the CVID results?
De_Monitor
$PHAR Hey , you haven't forgotten your promise to publish the CVID trial results, have you? November is already drawing to a close, and investors are still waiting. A little less silence and a little more transparency would be appreciated.
JFais
Face similar dilemma- want best r/r setups for my portfolio and those who follow me Same time, prefer higher/ decent daily volume so it's easier to bail when I'm wrong (don't want ppl to get burned) However, sometimes attractive r/r wins out (ie. full size position in $PHAR @ $10)
Ruconestor
$PHAR Beursblik: Jefferies verhoogt koersdoel Pharming 09-nov-2026 07:46 Ziet grote marktkans in CVID. (ABM FN-Dow Jones) Jefferies heeft het koersdoel voor Pharming verhoogd van 2,00 naar 2,30 euro, met behoud van het koopadvies, vanwege een hogere ingeschatte kans dat Joenja bij de aandoening CVID een succes kan worden. Dat bleek maandag uit een analistenrapport van de zakenbank. De Fase 2-gegevens voor Joenja bij de zeldzame aandoening Common Variable Immunodeficiency (CVID), die deze maand verwacht worden, bieden mogelijk meer kans op een blockbuster van circa 1 miljard dollar, die aanzienlijk groter is dan de 300 miljoen dollar voor de indicatie APDS die al op de markt is.
shoc24
$PHAR Reported today: EPS of $0.30 vs. $0.15 expected (+100.0%, beat). Revenue of $118M vs. $118M expected (0.0%, in line). I used Stock Meadow’s earnings dashboard to review the results.
Ruconestor
$PHAR Strong progress on Joenja expansion including U.S. pediatric label and launches in Germany and Japan Announced positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation and Phase II topline data in broader CVID patient population expected in November 2026 Pharming to host a conference call today at 13:30 CET (8:30 am EDT) Leiden, the Netherlands, October 27, 2026

Advertisement|Remove ads.